oral glp-1 drugs in development Lesson: Semaglutide: A New Receptor Agonist Product for the Treatment of Type 2 Diabetes Lilly is now pharma's top
Description
2018;6(17):e13852
This wasnt a small signal in a noisy dataset it was a dramatic, statistically robust finding that prompted multiple follow-up investigations
Berlin-Chemie and Roche (speakers bureau)
Most patients lose 58% of body weight
Because of a shortage of brand-name drugs, it was legal
Auto-renewal on subscriptions
